[vc_row el_class=”mr-b-26″][vc_column][vc_column_text single_style=””]<\/p>\n
Table of Contents<\/b><\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=”7112″ img_size=”full”][vc_column_text single_style=””]Figure 1. The Dual Edge of Folate: DNA Health, Supplementation, and Autism Care. <\/b>This infographic illustrates folate\u2019s paradoxical role in health, showing how its benefits and risks depend on dose, genetic background, and clinical context. On the left<\/i><\/span>, Essential for DNA Health<\/b> highlights folate\u2019s central role in one-carbon metabolism, supporting DNA methylation, repair, and genomic stability. Adequate folate intake prevents mutations and maintains healthy cell division, while deficiency is linked to hypomethylation, chromosomal instability, and increased cancer risk. Emerging DNA methylation biomarkers underscore its importance as a guardian of genomic integrity. In the center<\/i><\/span>, Complexity of Supplementation<\/b> emphasizes that while folate supplementation can correct deficiencies, excess intake risks hypermethylation and inappropriate gene silencing. Genetic subgroups, such as individuals with MTHFR polymorphisms, may require tailored doses, and safe thresholds remain under investigation. This reflects the delicate balance between protection and disruption, reminding us that \u201cmore\u201d is not always better. On the right<\/i><\/span>, Implications for Autism Care<\/b> show how folinic acid and high folate intake are sometimes used to support neurodevelopment in children with autism. Yet supraphysiological dosing may alter methylation patterns, raising concerns about long-term cancer risk. Precision in dosing is therefore crucial, especially in pediatric populations, to balance therapeutic promise against unintended genomic consequences. Together, the figure conveys folate\u2019s dual nature<\/i>\u2014as both protector and potential disruptor<\/i><\/span>\u2014underscoring the need for individualized, context-specific approaches to supplementation and therapy.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”introduction”][vc_column][vc_custom_heading text=”Introduction”][vc_column_text single_style=”” el_id=”blog-scroll-point-1″]Folate, Methylation, and the Delicate Balance of Genomic Integrity<\/b> The dual effect paradigm<\/b>\u2014where folate acts as both protector and potential disruptor\u2014has emerged from decades of experimental and clinical studies. Genomic hypomethylation<\/b>, often observed in folate deficiency, destabilizes chromosomal architecture and predisposes to recombination events. Conversely, promoter hypermethylation<\/b> of tumor suppressor genes under conditions of altered folate metabolism can silence critical pathways of cellular defense. This paradox mirrors the methylation abnormalities seen in epithelial cancers, lending credence to the hypothesis that folate status is a determinant of cancer risk [1 \u2013 9].<\/p>\n Within this framework, a contemporary concern has surfaced: whether indiscriminate consumption of excess folinic acid<\/b>\u2014particularly in vulnerable populations such as children with autism spectrum disorder (ASD)<\/b>\u2014might inadvertently increase long-term cancer risk. Folinic acid (5-formyltetrahydrofolate) is widely used in clinical practice, including as an adjunct in ASD management, where it has shown promise in improving language and behavioral outcomes in subsets of children with folate receptor autoantibodies<\/b>. However, scientific literature cautions that supraphysiological folate exposure may alter DNA methylation dynamics<\/b>, potentially fostering site-specific hypermethylation<\/b> of tumor suppressor genes or enhancing susceptibility to C\u2192T transition mutations<\/b> in hypermutable regions such as p53 exons 5\u20138<\/b>. While direct evidence linking folinic acid supplementation in autistic children to carcinogenesis is currently lacking, the broader body of research on folate\u2019s dual effects in cancer biology suggests that dose, duration, genetic background (e.g., MTHFR polymorphisms), and tissue environment<\/b> are critical determinants of outcome (see Figure 1<\/b>) [10].<\/p>\n Thus, the challenge is not simply to recognize folate as a nutrient essential for health, but to appreciate its nuanced role as a double-edged sword<\/b>. The following synthesis explores how folate and other one-carbon nutrients modulate DNA methylation at both genomic and gene-specific levels<\/b>, highlighting the delicate balance between protection and risk, and underscoring why precision in supplementation<\/b>\u2014rather than indiscriminate use<\/i><\/span>\u2014is vital for safeguarding long-term genomic stability.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”blog-scroll-point-1″][vc_column][vc_custom_heading text=”I. Biological Methylation: The Folate Connection” use_theme_fonts=”yes”][vc_column_text single_style=””]S-Adenosylmethionine as the Universal Methyl Donor<\/b> [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=”7116″ img_size=”full”][vc_column_text single_style=””]Figure 3. DNA methylation and demethylation cycle.<\/b> DNA methylation involves the addition of a methyl group<\/i><\/b> (CH\u2083)<\/i><\/b> from the universal donor S-adenosylmethionine<\/i><\/b> (SAM<\/i><\/b>) to the fifth carbon of cytosine <\/b>(C<\/b>), facilitated by DNA methyltransferase (DNMT<\/b>), resulting in 5-methylcytosine (5-mC<\/b>). This process produces S-adenosylhomocysteine (SAH<\/b>) as a byproduct. DNA demethylation occurs through passive or active processes<\/i><\/b>:<\/b> (1) Passive demethylation<\/b> – Happens over successive cell divisions without the addition of new methyl groups. (2) Active demethylation<\/b> – Involves the sequential conversion of 5-mC<\/b> to 5-hydroxymethylcytosine (5-hmC<\/b>), then to derivatives like 5-formylcytosine (5-fC<\/b>) and 5-carboxylcytosine (5-caC<\/b>), ultimately returning to cytosine (C<\/b>). This process is regulated by the ten-eleven translocation<\/b> (TET<\/b>) family of proteins<\/b>. The combined actions of these mechanisms ensure that DNA methylation and demethylation are dynamic processes, crucial for regulating gene expression and maintaining cellular function.[\/vc_column_text][vc_column_text single_style=””]Functional Significance of CpG Methylation<\/b> Beyond transcriptional control, DNA methylation safeguards genetic integrity<\/b>, influences chromatin organization<\/b>, and modulates mutational susceptibility<\/b>. For example, in p53<\/b>, sites prone to C\u2192T transition mutations<\/b> frequently overlap with methylcytosine residues<\/b>\u2014a concordance strongly suggestive of causal linkage, though the precise mechanism remains debated. [\/vc_column_text][vc_column_text single_style=””]The reasons why certain CpG islands are particularly vulnerable to hypermethylation<\/b> in neoplasia remain unclear. However, genomic hypomethylation<\/b> is consistently observed in dysplastic (premalignant) tissues<\/b> and is considered one of the earliest molecular events in carcinogenesis<\/b>. Studies reveal that the degree of genomic methylation decreases incrementally<\/b> with advancing grades of neoplasia, reinforcing its role in tumor progression (see Figure 4<\/b> and Figure 5<\/b>).[\/vc_column_text][vc_column_text single_style=””]Gene-Specific vs. Genomic Effects<\/b> The SAM\/SAH ratio<\/b> is often considered a proxy for the methylation potential<\/b> of a biological system. However, its utility lies mainly in reflecting S-AdoHcy accumulation<\/b>, since SAM levels are typically maintained within a narrow range by feedback regulation involving methylene-THF reductase (MTHFR)<\/b>. Importantly, the hydrolysis of SAH to homocysteine<\/b> is thermodynamically unfavorable, favoring SAH accumulation and amplifying its inhibitory effect (see Figure 2<\/b>).<\/p>\n Experimental data illustrate this paradox: in rats with severe folate deficiency<\/b>, colonic mucosal folate concentrations decreased by nearly 100-fold<\/b>, while colonic SAM levels increased sixfold<\/b>. Yet, mucosal SAM concentrations remained unchanged<\/b>, and DNA methylation did not correlate predictably<\/b> with SAM levels. Similar findings have been reported in cell culture, underscoring that SAM alone is a poor predictor<\/b> of genomic methylation. In sum, while SAM and SAH are partial determinants<\/b>, their concentrations correlate with DNA methylation in an unpredictable fashion<\/b>, reflecting the influence of additional regulatory factors [7 \u2013 9].[\/vc_column_text][vc_column_text single_style=””]Preclinical and Clinical Evidence: Magnitude, Duration, and Tissue Specificity<\/b> Comparative rodent studies highlight this variability: one experiment inducing severe folate deficiency<\/b> readily demonstrated genomic hypomethylation<\/b>, whereas a parallel study with moderate depletion<\/b> showed no evidence<\/b> of demethylation. Typically, genomic hypomethylation emerges within weeks<\/b>, though the precise onset remains undefined.[\/vc_column_text][vc_column_text single_style=””]The Colonic Mucosa: A Resistant Yet Vulnerable Tissue<\/b> [\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-5″][vc_column][vc_custom_heading text=”V. Human Evidence: Folate Status and Genomic DNA Methylation” el_class=”blog-text-35795″][vc_column_text single_style=””]Controlled Studies and Genetic Interactions<\/b> Cross-sectional studies in free-living populations<\/b> suggest that low folate status<\/b> can also diminish genomic methylation, but primarily in individuals carrying the homozygous TT genotype<\/b> of the common MTHFR 677C\u2192T polymorphism<\/b>. This nutrient\u2013gene interaction highlights the importance of genetic background<\/b> in determining susceptibility. Additional studies are needed to confirm whether folate-related hypomethylation in free-living populations is restricted to this genotype.<\/p>\n The tissue-specific sensitivity observed in these studies is biologically plausible. Bone marrow<\/b>, with its extraordinarily high rate of DNA synthesis, appears particularly vulnerable to folate limitation. Similarly, the colonic mucosa<\/b>, another tissue with rapid turnover, has been repeatedly identified as susceptible to folate depletion. This vulnerability may help explain why the epidemiological link between low folate intake<\/b> and cancer risk<\/b> is strongest for the colorectum<\/b>.[\/vc_column_text][vc_column_text single_style=””]Challenges in Detecting Folate Effects in Populations<\/b> Intervention Trials: Supplementation Outcomes<\/b>\n
\nFolate and its derivatives occupy a central role in one-carbon metabolism<\/b>, serving as indispensable cofactors for the synthesis of S-adenosylmethionine (SAM)<\/b>, the universal methyl donor. Through this pathway, folate orchestrates the methylation of DNA, RNA, proteins, and phospholipids<\/b>, thereby safeguarding genomic integrity, regulating gene expression, and maintaining cellular homeostasis. Yet, as our discussion has underscored, the relationship between folate and methylation is not linear but bidirectional and context-dependent<\/b>. Both deficiency<\/b> and excess supplementation<\/b> can perturb methylation patterns, producing either global hypomethylation<\/b> or gene-specific hypermethylation<\/b>, each with profound implications for carcinogenesis [1 \u2013 9].<\/p>\n
\nIn mammalian cells, most methylation reactions<\/b> rely on S-adenosylmethionine (S-AdoMet or SAM)<\/b> as the principal methyl donor. The labile methyl group<\/b> of SAM originates from methionine<\/b>, which itself acquires this moiety from 5-methyltetrahydrofolate (5-methyl-THF)<\/b>\u2014a critical folate derivative essential for the de novo<\/i> synthesis of methionine. Each SAM-mediated methylation reaction yields two products: the methylated target molecule<\/b> and S-adenosylhomocysteine (S-AdoHcy or SAH)<\/b>. Importantly, SAH is a potent inhibitor<\/b> of nearly all SAM-dependent methyltransferases, with K<\/b>i<\/b> values ranging between 2\u20136 \u03bcM<\/b>, underscoring its regulatory role in cellular methylation capacity (see Figure 2<\/b>).[\/vc_column_text][vc_column_text single_style=””]Targets of Methylation and Folate Deficiency<\/b>
\nThe reach of SAM-dependent methylation extends across DNA, RNA, proteins, and phospholipids<\/b> (see Figure 2<\/b>). Experimental studies consistently demonstrate that inadequate one-carbon nutrient supply<\/b> reduces methylation levels in each of these biomolecules. Among them, DNA methylation abnormalities<\/b> have attracted the greatest attention, particularly in the context of carcinogenesis<\/b>, where folate status profoundly influences methylation dynamics. By contrast, the potential pro-transformational effects<\/b> of aberrant methylation in proteins, RNA, and phospholipids remain relatively underexplored, with only limited studies addressing these pathways.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=”7117″ img_size=”full”][vc_column_text single_style=””]Figure 2. Cytosolic One-Carbon Metabolism: Folate-Driven Interconversions and Methylation Pathways. <\/b>Schematic representation of one-carbon metabolism<\/i><\/u> within the cytosol of mammalian cells, highlighting the dynamic interconversion of folate coenzymes and their roles in nucleotide synthesis<\/i><\/span> and methylation<\/i><\/span>. Key intermediates include tetrahydrofolate (THF)<\/b>, dihydrofolate (DHF)<\/b>, S-adenosylmethionine (S-AdoMet)<\/b>, S-adenosylhomocysteine (S-AdoHcy)<\/b>, and dimethylglycine (DMG)<\/b>. Enzymatic steps are catalyzed by: 1. Methionine synthase<\/i><\/u> (MS)<\/b>; 2. Betaine-homocysteine methyltransferase<\/i><\/u> (BHMT)<\/b>; 3. Methylenetetrahydrofolate reductase<\/i><\/u> (MTHFR)<\/b>; 4. Serine hydroxymethyltransferase<\/i><\/u> (SHMT)<\/b>; 5. Cystathionine \u03b2-synthase<\/i><\/u> (CBS)<\/b>.
\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_id=”blog-scroll-point-2″][vc_column][vc_custom_heading text=”II. DNA Methylation and Cancer” use_theme_fonts=”yes”][vc_column_text single_style=””]CpG Sites and DNA Methyltransferases<\/b>
\nIn mammalian genomes, DNA methylation<\/b> occurs almost exclusively at the 5-carbon of cytosine residues<\/b> preceding guanine\u2014known as CpG sites<\/b>. Approximately 50\u201370% of CpG residues<\/b> in the adult human genome are methylated. These sites cluster in CpG islands<\/b>, typically located in the 5\u2032-untranslated regions (UTRs)<\/b> of genes. Under basal conditions, CpG islands remain largely unmethylated<\/b>, whereas dispersed CpG sites within coding regions are heavily methylated<\/b>.[\/vc_column_text][vc_column_text single_style=””]The conversion of cytosine to 5-methylcytosine<\/b> is catalyzed by DNA methyltransferases (DNMTs)<\/b> (see Figure 3<\/b>).<\/p>\n\n
\nThe precision with which cells preserve CpG methylation patterns<\/b> highlights their importance. Some patterns are established during embryogenesis<\/b> or early postnatal life<\/b>, while others act as lifelong adaptive mechanisms<\/b>, enabling organisms to respond to environmental cues and maintain homeostasis. CpG islands in the 5\u2032-UTR<\/b> are particularly critical, regulating gene expression<\/b>: demethylation<\/i> often enhances transcription, while methylation<\/i> suppresses it (see Figure 4<\/b> and Figure 5<\/b>).<\/p>\n
\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-3″][vc_column][vc_custom_heading text=”III. Aberrant Methylation in Carcinogenesis” el_class=”blog-text-35795″][vc_column_text single_style=””]The Paradox of Hypomethylation and Hypermethylation<\/b>
\nEpithelial cancers often exhibit two paradoxical methylation abnormalities:<\/p>\n\n
\nCancer evolution is often attributed to gene-specific methylation changes<\/b> rather than global phenomena. Indeed, hypermethylation of promoter CpG islands<\/b> in tumor suppressor genes<\/b>\u2014with consequent gene silencing<\/b>\u2014is a hallmark of many cancers. Conversely, hypomethylation at critical sites<\/b> may disrupt imprinting<\/b>, abolishing the suppressed expression of one allele and promoting dedifferentiation and tumorigenesis<\/b>, as demonstrated in colorectal cancer models<\/b> [1 \u2013 6].[\/vc_column_text][vc_column_text single_style=””]Yet, genomic hypomethylation<\/b> itself may be causal<\/b>. By destabilizing DNA, it increases susceptibility to mitotic recombination<\/b>, facilitating chromosomal breaks, translocations, and allelic loss<\/b>\u2014all of which accelerate malignant transformation (see Figure 5<\/b>).
\n[\/vc_column_text][vc_single_image image=”7115″ img_size=”full”][vc_column_text single_style=””]Figure 4. Core Epigenetic Mechanisms Governing Gene Expression and Cellular Identity. <\/b>This figure illustrates the three principal epigenetic pathways that regulate gene expression without altering the underlying DNA sequence: 1.<\/b> DNA Methylation<\/b>: The addition of methyl groups (CH\u2083) to cytosine residues within CpG dinucleotides, typically leading to transcriptional repression. Methylation patterns are essential for genomic imprinting, X-chromosome inactivation, and silencing of repetitive elements. Aberrant methylation\u2014either global hypomethylation or promoter hypermethylation\u2014is implicated in carcinogenesis and developmental disorders. 2. Histone Modifications (Histone Code)<\/b>: Post-translational modifications of histone tails\u2014including methylation, acetylation, phosphorylation, and ubiquitination<\/span>\u2014alter chromatin structure and accessibility. Histone acetylation generally promotes transcriptional activation by loosening chromatin, while histone methylation can either activate or repress gene expression depending on the specific residue and context (e.g., H3K4me3 vs. H3K27me3). These modifications form a dynamic \u201chistone code\u201d interpreted by reader proteins to orchestrate cell-type\u2013specific transcriptional programs. 3.<\/b> RNA-Based Mechanisms<\/b>: Non-coding RNAs\u2014including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and small interfering RNAs (siRNAs)\u2014modulate gene expression post-transcriptionally and guide chromatin remodeling complexes to specific genomic loci. These RNA species play critical roles in development, immune regulation, and disease pathogenesis, and are increasingly recognized as key mediators of epigenetic inheritance. Together, these mechanisms form a multilayered regulatory network that governs cellular identity, developmental plasticity, and disease susceptibility.<\/span> Their interplay is especially relevant in contexts such as cancer, neurodevelopmental disorders, and aging, where epigenetic dysregulation can have profound consequences.
\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″ el_id=”blog-scroll-point-4″][vc_column][vc_custom_heading text=”IV. Effects of Folate and One-Carbon Nutrients on DNA Methylation” el_class=”blog-text-35795″][vc_column_text single_style=””]Genomic Methylation: Patterns and Paradoxes<\/b>
\nDepletion of folate<\/b>\u2014whether in cultured cells, intact animals, or humans\u2014has been shown to induce genomic DNA hypomethylation<\/b> under certain experimental conditions. Intriguingly, it may also trigger site-specific hypermethylation<\/b>, a dual pattern that mirrors the abnormalities observed in epithelial cancers<\/b> [1 -6]. This resemblance strengthens the hypothesis that inadequate folate availability<\/b> promotes carcinogenesis<\/b> through disruptions in DNA methylation. Yet, as in cancer biology, the precise mechanisms driving the coexistence of global hypomethylation<\/b> and localized hypermethylation<\/b> remain poorly defined.[\/vc_column_text][vc_column_text single_style=””]Inconsistencies Across Studies<\/b>
\nDespite compelling evidence, changes in DNA methylation following folate depletion have not been consistently reproducible<\/b>. Variability may stem from differences in methodologies<\/b> used to measure methylation, or from confounding factors<\/b> such as age<\/b>, which itself influences methylation status. Moreover, methylation changes are dynamic<\/b>, fluctuating during the course of nutrient depletion. For example, serial studies in rodents fed a methyl-deficient diet<\/b> (lacking choline, B12, and folate<\/i>) revealed an initial wave of genomic hypomethylation<\/b> that intensified over time. This was accompanied by an up-regulation of DNA methyltransferase activity<\/b>, possibly as a compensatory response. Subsequently, site-specific hypermethylation<\/b> emerged at loci receptive to enhanced methyltransferase activity. Such temporal dynamics may explain why some investigators report no change<\/b>, or even paradoxical increases<\/b>, in genomic methylation under folate deprivation.[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=”blog-text-35795″][vc_column][vc_single_image image=”7114″ img_size=”full”][vc_column_text single_style=””]Figure 5. Cancer Epigenetics: Key Mechanisms of Gene Regulation Gone Awry. <\/b>This figure illustrates the major epigenetic disruptions that contribute to cancer development. Unlike genetic mutations, these changes do not alter the DNA sequence itself but instead reshape how genes are switched \u201con\u201d or \u201coff\u201d<\/i><\/span> and how the genome is packaged and interpreted<\/i><\/span>. Together, they destabilize cellular identity and promote tumor growth: 1. Promoter Hypermethylation<\/b> \u2013 Excess methylation at gene start sites silences tumor-suppressor genes. For example<\/i><\/span>: p16INK4A<\/i> and hMLH1<\/i> are frequently hypermethylated in colorectal and gastric cancers, blocking cell-cycle control and DNA repair. 2. Genome-Wide Hypomethylation<\/b> \u2013 Loss of methylation across the genome destabilizes DNA and activates harmful elements. For example<\/i><\/span>: Hypomethylation of LINE-1 repetitive elements in lung and bladder cancers leads to chromosomal instability. 3. Reduced Histone Acetylation<\/b> \u2013 Lower acetylation tightens chromatin, restricting access to protective genes. For example<\/i>: Reduced histone H3 acetylation in breast cancer cells correlates with silencing of estrogen receptor target genes. 4. Reader Mutations<\/b> \u2013 Mutations in proteins that \u201cread\u201d epigenetic marks misdirect gene regulation. For example<\/i><\/span>: BRD4 mutations alter enhancer activity in leukemia, driving uncontrolled cell proliferation. 5. Abnormal Methylation Enzyme Mutations<\/b> \u2013 Mutations in enzymes that add or remove methyl groups disrupt normal patterns. For example<\/i><\/span>: DNMT3A mutations in acute myeloid leukemia (AML) cause widespread abnormal methylation and poor prognosis. 6. SWI\/SNF Complex Loss-of-Function<\/b> \u2013 This chromatin remodeling complex normally opens DNA for transcription; its loss impairs gene regulation. For example<\/i><\/span>: SMARCB1<\/i> mutations are hallmarks of malignant rhabdoid tumors. 7. Abnormal Chromatin Structure<\/b> \u2013 Altered folding of DNA changes accessibility of key genes. For example<\/i><\/span>: In prostate cancer, abnormal chromatin looping brings oncogenes under strong enhancers, boosting their activity. Together, these epigenetic mechanisms silence protective pathways, destabilize the genome, and activate oncogenic programs<\/span>\u2014laying the foundation for cancer initiation and progression.[\/vc_column_text][vc_column_text single_style=””]Biochemical Determinants: SAM, SAH, and the Ratio That Matters<\/b>
\nMechanistically, genomic hypomethylation<\/b> induced by folate depletion appears to be driven primarily by increased concentrations of S-adenosylhomocysteine (S-AdoHcy)<\/b>, a potent methyltransferase inhibitor<\/b>. In contrast, limitations in S-adenosylmethionine (S-AdoMet or SAM)<\/b> availability play a lesser role. This is supported by animal models with genetically engineered defects in SAM synthesis, where methylation changes were not solely explained by SAM depletion.<\/p>\n
\nOn a genomic level<\/b>, hypomethylation induced by one-carbon nutrient depletion has been documented in both animal models<\/b> and human studies<\/b>. However, its occurrence depends on the severity and duration<\/b> of depletion, and whether multiple nutrients<\/b> are simultaneously deficient. Tissue specificity further complicates interpretation.<\/p>\n
\nThe colonic mucosa<\/b> exemplifies tissue-specific responses. Despite observations in cultured human colonocytes, intact animal studies consistently show that the colonic mucosa is highly resistant<\/b> to hypomethylation under isolated folate depletion<\/b>.\u00a0[\/vc_column_text][vc_column_text single_style=””]Yet, two factors can sensitize it:<\/p>\n\n
\nSustained dietary folate inadequacy<\/b> has been shown to produce genomic DNA hypomethylation<\/b> in humans, though the number of intervention studies remains limited. The most convincing evidence comes from highly controlled metabolic unit studies<\/b>, where subjects either resided within the unit or obtained all meals under strict supervision. In these settings, white blood cell DNA hypomethylation<\/b> was observed when mean plasma folate concentrations fell to 9.0\u201313.7 nmol\/L (\u22484.1\u20136.3 ng\/mL)<\/b>\u2014a relatively modest systemic depletion.<\/p>\n
\nDetecting folate\u2019s impact on genomic methylation in the general population<\/b> is more difficult than in controlled metabolic units. In ambulatory adults, three cross-sectional analyses<\/b> found that folate status explained little of the variance in methylation. However, Friso and colleagues<\/b> demonstrated a substantial effect when accounting for MTHFR genotype<\/b>: individuals with the TT genotype<\/b> and low folate status<\/b> consistently exhibited diminished genomic methylation. This underscores the importance of considering nutrient\u2013gene interactions<\/b> in population studies.<\/p>\n
\nSeveral human intervention trials<\/b> have examined whether folic acid supplementation<\/b> can restore or enhance genomic methylation. Results are mixed:[\/vc_column_text][vc_column_text single_style=””]<\/p>\n\n
\n
\n
\n